PT - JOURNAL ARTICLE AU - Armaly, Zaher A. AU - Nitzan, Yaacov AU - Chernin, Gil AU - Aronson, Doron TI - Harnessing the Eccrine Sweat Glands for the Management of Interdialytic Weight Gain – A Pilot Study AID - 10.1101/2024.04.15.24304270 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.15.24304270 4099 - http://medrxiv.org/content/early/2024/04/16/2024.04.15.24304270.short 4100 - http://medrxiv.org/content/early/2024/04/16/2024.04.15.24304270.full AB - Background Hemodialysis patients are susceptible to excess volume accumulation, particularly over the 2-day interval (long interdialytic gap), resulting in higher interdialytic weight gain (IDWG).Methods We employed a novel device designed to enhance fluid and salt loss by activating of the eccrine sweat glands to treat IDWG. Patients eligible for the study were undergoing regular hemodialysis for ≥3 months, without residual renal function, and with IDWG (as a percentage of IDWG/dry body weight) ≥2.5%. Treatments were administered at the patient’s home. The primary performance endpoint was differences in weight gain over long interdialytic period with the device compared to the control period. Secondary exploratory endpoints included the need for ultrafiltration (UF) rate > 10 mL/kg/h in the post-interval dialysis.Results Five patients were enrolled into the pilot study (age range 26 to 69 years, 3 women). The hourly mean weight loss from sweat was 186 ± 45 gr/h. The average procedure length was 4.5 hours with an average fluid loss of 899 ± 283 gr per procedure. The average least-squares mean absolute difference between the control and treatment periods was -2.0%; (95% confidence interval [CI], -2.9% to -1.2%, P<0001). The reduction in IDWG was associated a reduction in UF rates, with a least-squares mean difference of -3.2 mL/Kg/min [95% CI -4.6 to -1.8] between the control and treatment periods (P<0.001), resulting in a safe UF rate (<10 mL/Kg/min) in all post-treatment sessions.Conclusion Enhancing sweat rate mitigated IDWG in hemodialysis patients. Together with trice weekly HD, this therapy more closely approximates the capacity of the native kidney to regulate extracellular volume and solute composition, similar to patients with substantial residual kidney function.Competing Interest StatementDoron Aronson is a consultant for AquaPass. Yaacov Nitzan is the CEO of AquaPass Ltd. The study was funded by AquaPass Ltd. Clinical TrialNCT06358365Funding StatementThe study was funded by AquaPass Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted with the approval of the institutional review boards at the Nazareth Hospital EMMS, Nazareth, Israel.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscrip